Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1247

1.

Chemical Imaging of Evolving Amyloid Plaque Pathology and Associated Aβ Peptide Aggregation in a Transgenic Mouse Model of Alzheimer's Disease.

Michno W, Wehrli P, Meier S, Sehlin D, Syvänen S, Zetterberg H, Blennow K, Hanrieder J.

J Neurochem. 2019 Oct 12. doi: 10.1111/jnc.14888. [Epub ahead of print]

PMID:
31605538
2.

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid.

Frankel R, Törnquist M, Meisl G, Hansson O, Andreasson U, Zetterberg H, Blennow K, Frohm B, Cedervall T, Knowles TPJ, Leiding T, Linse S.

Commun Biol. 2019 Oct 8;2:365. doi: 10.1038/s42003-019-0612-2. eCollection 2019.

3.

Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.

Chatterjee P, Zetterberg H, Goozee K, Lim CK, Jacobs KR, Ashton NJ, Hye A, Pedrini S, Sohrabi HR, Shah T, Asih PR, Dave P, Shen K, Taddei K, Lovejoy DB, Guillemin GJ, Blennow K, Martins RN.

J Neuroinflammation. 2019 Oct 10;16(1):186. doi: 10.1186/s12974-019-1567-4.

4.

Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease.

Kehoe PG, Al Mulhim N, Zetterberg H, Blennow K, Miners JS.

J Alzheimers Dis. 2019 Oct 3. doi: 10.3233/JAD-190721. [Epub ahead of print]

PMID:
31594235
5.

Biomarker-guided clustering of Alzheimer's disease clinical syndromes.

Toschi N, Lista S, Baldacci F, Cavedo E, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Melo Dos Santos A, Epelbaum S, Lamari F, Genthon R, Habert MO, Dubois B, Floris R, Garaci F, Vergallo A, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Neurobiol Aging. 2019 Sep 10;83:42-53. doi: 10.1016/j.neurobiolaging.2019.08.032. [Epub ahead of print]

6.

Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection.

Yilmaz A, Mellgren Å, Fuchs D, Nilsson S, Blennow K, Zetterberg H, Gisslén M.

Infect Dis (Lond). 2019 Sep 26:1-9. doi: 10.1080/23744235.2019.1670352. [Epub ahead of print]

PMID:
31556765
7.

Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects.

Lue LF, Pai MC, Chen TF, Hu CJ, Huang LK, Lin WC, Wu CC, Jeng JS, Blennow K, Sabbagh MN, Yan SH, Wang PN, Yang SY, Hatsuta H, Morimoto S, Takeda A, Itoh Y, Liu J, Xie H, Chiu MJ.

Front Aging Neurosci. 2019 Sep 3;11:222. doi: 10.3389/fnagi.2019.00222. eCollection 2019.

8.

Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data.

Wehrli PM, Michno W, Blennow K, Zetterberg H, Hanrieder J.

J Am Soc Mass Spectrom. 2019 Sep 16. doi: 10.1007/s13361-019-02327-y. [Epub ahead of print]

PMID:
31529404
9.

Acute symptomatic seizures and epilepsy after mechanical thrombectomy.

Eriksson H, Löwhagen Hendén P, Rentzos A, Pujol-Calderón F, Karlsson JE, Höglund K, Blennow K, Zetterberg H, Rosengren L, Zelano J.

Epilepsy Behav. 2019 Sep 13:106520. doi: 10.1016/j.yebeh.2019.106520. [Epub ahead of print]

PMID:
31526644
10.

CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology.

Miners JS, Kehoe PG, Love S, Zetterberg H, Blennow K.

Alzheimers Res Ther. 2019 Sep 14;11(1):81. doi: 10.1186/s13195-019-0534-8.

11.

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease.

Sjödin S, Brinkmalm G, Öhrfelt A, Parnetti L, Paciotti S, Hansson O, Hardy J, Blennow K, Zetterberg H, Brinkmalm A.

Alzheimers Res Ther. 2019 Sep 14;11(1):82. doi: 10.1186/s13195-019-0533-9.

12.

Dementia and CSF-Biomarkers for Alzheimer's Disease Predict Mortality after Acute Hip Fracture.

Dutkiewicz R, Zetterberg H, Andreasson U, Blennow K, Nellgård B.

Acta Anaesthesiol Scand. 2019 Sep 11. doi: 10.1111/aas.13472. [Epub ahead of print]

PMID:
31508810
13.

Sex differences in the genetic predictors of Alzheimer's pathology.

Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B, Bush WS, Gifford KA, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Deming Y, Chao MJ, Huentelman M, Martin ER, Hamilton-Nelson K, Shaw LM, Trojanowski JQ, Peskind ER, Cruchaga C, Pericak-Vance MA, Goate AM, Cox NJ, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M; Alzheimer’s Disease Genetics Consortium and the Alzheimer’s Disease Neuroimaging Initiative, Bennett DA, Schneider JA, Jefferson AL, Hohman TJ.

Brain. 2019 Sep 1;142(9):2581-2589. doi: 10.1093/brain/awz206.

PMID:
31497858
14.

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Zetterberg H, Baker S, Morgan BP, Streffer J, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ.

Alzheimers Dement. 2019 Sep 5. pii: S1552-5260(19)35118-0. doi: 10.1016/j.jalz.2019.06.4951. [Epub ahead of print]

15.

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1.

Wasling P, Malmeström C, Blennow K.

Neurol Neuroimmunol Neuroinflamm. 2019 Sep 4;6(6). pii: e613. doi: 10.1212/NXI.0000000000000613. Print 2019 Nov. No abstract available.

16.

Growth factors and neurotrophins in patients with stress-related exhaustion disorder.

Sjörs Dahlman A, Blennow K, Zetterberg H, Glise K, Jonsdottir IH.

Psychoneuroendocrinology. 2019 Aug 20;109:104415. doi: 10.1016/j.psyneuen.2019.104415. [Epub ahead of print]

17.

Was it worth it? Older adults' experiences of participating in a population-based cohort study - a focus group study.

Dahlin-Ivanoff S, Sterner TR, Blennow K, Skoog I, Erhag HF.

BMC Geriatr. 2019 Aug 19;19(1):224. doi: 10.1186/s12877-019-1238-4.

18.

Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.

Chatterjee P, Elmi M, Goozee K, Shah T, Sohrabi HR, Dias CB, Pedrini S, Shen K, Asih PR, Dave P, Taddei K, Vanderstichele H, Zetterberg H, Blennow K, Martins RN.

J Alzheimers Dis. 2019;71(3):775-783. doi: 10.3233/JAD-190533.

PMID:
31424403
19.

The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.

Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube U, Farias FG, Bradley J, Budde J, Ibanez L, Fernandez MV, Blennow K, Zetterberg H, Heslegrave A, Johansson PM, Svensson J, Nellgård B, Lleo A, Alcolea D, Clarimon J, Rami L, Molinuevo JL, Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Ewers M, Harari O, Haass C, Brett TJ, Benitez BA, Karch CM, Piccio L, Cruchaga C.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaau2291. doi: 10.1126/scitranslmed.aau2291.

PMID:
31413141
20.

Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis.

Gaetani L, Eusebi P, Mancini A, Gentili L, Borrelli A, Parnetti L, Calabresi P, Sarchielli P, Blennow K, Zetterberg H, Di Filippo M.

Mult Scler Relat Disord. 2019 Jul 27;35:228-232. doi: 10.1016/j.msard.2019.07.025. [Epub ahead of print]

PMID:
31404762
21.

Altered CSF levels of monoamines in hereditary spastic paraparesis 10: A case series.

Andréasson M, Lagerstedt-Robinson K, Samuelsson K, Solders G, Blennow K, Paucar M, Svenningsson P.

Neurol Genet. 2019 Jun 12;5(4):e344. doi: 10.1212/NXG.0000000000000344. eCollection 2019 Aug.

22.

Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.

Osborn KE, Alverio JM, Dumitrescu L, Pechman KR; Alzheimer’s Disease Neuroimaging Initiative, Gifford KA, Hohman TJ, Blennow K, Zetterberg H, Jefferson AL.

J Alzheimers Dis. 2019;71(1):281-290. doi: 10.3233/JAD-190077.

PMID:
31381510
23.

Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction.

Pedersen A, Stanne TM, Nilsson S, Klasson S, Rosengren L, Holmegaard L, Jood K, Blennow K, Zetterberg H, Jern C.

J Neurol. 2019 Aug 2. doi: 10.1007/s00415-019-09477-9. [Epub ahead of print]

PMID:
31375988
24.

Plasma neurofilament light chain concentration is increased in anorexia nervosa.

Nilsson IAK, Millischer V, Karrenbauer VD, Juréus A, Salehi AM, Norring C, von Hausswolff-Juhlin Y, Schalling M, Blennow K, Bulik CM, Zetterberg H, Landén M.

Transl Psychiatry. 2019 Aug 1;9(1):180. doi: 10.1038/s41398-019-0518-2.

25.

Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression.

De S, Whiten DR, Ruggeri FS, Hughes C, Rodrigues M, Sideris DI, Taylor CG, Aprile FA, Muyldermans S, Knowles TPJ, Vendruscolo M, Bryant C, Blennow K, Skoog I, Kern S, Zetterberg H, Klenerman D.

Acta Neuropathol Commun. 2019 Jul 26;7(1):120. doi: 10.1186/s40478-019-0777-4.

26.

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease.

Fossati S, Ramos Cejudo J, Debure L, Pirraglia E, Sone JY, Li Y, Chen J, Butler T, Zetterberg H, Blennow K, de Leon MJ.

Alzheimers Dement (Amst). 2019 Jun 28;11:483-492. doi: 10.1016/j.dadm.2019.05.001. eCollection 2019 Dec.

27.

Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid.

Johansson V, Erhardt S, Engberg G, Kegel M, Bhat M, Schwieler L, Blennow K, Zetterberg H, Cannon TD, Wetterberg L, Hultman CM, Landén M.

Eur Arch Psychiatry Clin Neurosci. 2019 Jul 13. doi: 10.1007/s00406-019-01042-9. [Epub ahead of print]

PMID:
31302732
28.

Characterization of Cerebrospinal Fluid BACE1 Species.

Lopez-Font I, Boix CP, Zetterberg H, Blennow K, Sáez-Valero J.

Mol Neurobiol. 2019 Jul 9. doi: 10.1007/s12035-019-01677-8. [Epub ahead of print]

PMID:
31290061
29.

Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum.

Allison SL, Koscik RL, Cary RP, Jonaitis EM, Rowley HA, Chin NA, Zetterberg H, Blennow K, Carlsson CM, Asthana S, Bendlin BB, Johnson SC.

Neuroimage Clin. 2019;23:101895. doi: 10.1016/j.nicl.2019.101895. Epub 2019 Jun 10.

30.

Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.

Wilke C, Pujol-Calderón F, Barro C, Stransky E, Blennow K, Michalak Z, Deuschle C, Jeromin A, Zetterberg H, Schüle R, Höglund K, Kuhle J, Synofzik M.

Clin Chem Lab Med. 2019 Sep 25;57(10):1556-1564. doi: 10.1515/cclm-2019-0015.

PMID:
31251725
31.

Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer's disease.

Sanfilippo C, Castrogiovanni P, Imbesi R, Kazakowa M, Musumeci G, Blennow K, Zetterberg H, Di Rosa M.

Brain Res. 2019 Oct 1;1720:146305. doi: 10.1016/j.brainres.2019.146305. Epub 2019 Jun 24.

PMID:
31247206
32.

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.

Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O.

JAMA Neurol. 2019 Jun 24. doi: 10.1001/jamaneurol.2019.1632. [Epub ahead of print]

33.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
34.

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures.

Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, Machulda MM, Kremers WK, Knopman DS, Jack C Jr, Petersen RC, Kern S.

Neurology. 2019 Jul 16;93(3):e252-e260. doi: 10.1212/WNL.0000000000007767. Epub 2019 Jun 10.

35.

Serum tau concentration after diving - an observational pilot study.

Rosén A, Oscarsson N, Kvarnström A, Gennser M, Sandström G, Blennow K, Seeman-Lodding H, Zetterberg H.

Diving Hyperb Med. 2019 Jun 30;49(2):88-95. doi: 10.28920/dhm49.2.88-95.

PMID:
31177514
36.

CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.

Jeppsson A, Wikkelsö C, Blennow K, Zetterberg H, Constantinescu R, Remes AM, Herukka SK, Rauramaa T, Nagga K, Leinonen V, Tullberg M.

J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1117-1123. doi: 10.1136/jnnp-2019-320826. Epub 2019 Jun 5.

37.

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype.

Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ; Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups.

Alzheimers Dement. 2019 Jul;15(7):888-898. doi: 10.1016/j.jalz.2019.04.001. Epub 2019 Jun 1.

PMID:
31164314
38.

Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease.

Minta K, Portelius E, Janelidze S, Hansson O, Zetterberg H, Blennow K, Andreasson U.

J Alzheimers Dis. 2019;69(4):1213-1220. doi: 10.3233/JAD-190187.

PMID:
31156172
39.

Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke.

Onatsu J, Vanninen R, Jäkälä P, Mustonen P, Pulkki K, Korhonen M, Hedman M, Zetterberg H, Blennow K, Höglund K, Herukka SK, Taina M.

J Stroke Cerebrovasc Dis. 2019 Aug;28(8):2242-2249. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.008. Epub 2019 May 28.

PMID:
31151840
40.

CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia.

Hansson O, Santillo AF, Meeter LH, Nilsson K, Landqvist Waldö M, Nilsson C, Blennow K, van Swieten JC, Janelidze S.

Ann Clin Transl Neurol. 2019 Mar 29;6(5):863-872. doi: 10.1002/acn3.763. eCollection 2019 May.

41.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019 May 27.

42.

Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.

Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A, Gentili L, Borrelli A, Portaccio E, Sarchielli P, Blennow K, Zetterberg H, Parnetti L, Calabresi P, Di Filippo M.

J Neurol. 2019 Sep;266(9):2157-2163. doi: 10.1007/s00415-019-09398-7. Epub 2019 May 25.

PMID:
31129709
43.

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL, Shaw LM, Hansson O, Doecke JD, Li QX, Teunissen C, Tumani H, Blennow K.

Clin Biochem. 2019 Oct;72:30-38. doi: 10.1016/j.clinbiochem.2019.05.005. Epub 2019 May 23.

44.

Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.

Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, Rutz S, Widmann M, Leinenbach A, Blennow K.

Clin Biochem. 2019 Oct;72:7-14. doi: 10.1016/j.clinbiochem.2019.05.006. Epub 2019 May 23.

45.

Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women.

Johansson L, Sacuiu S, Kern S, Guo X, Zetterberg H, Blennow K, Zettergren A, Skoog I.

Neurobiol Aging. 2019 Aug;80:111-115. doi: 10.1016/j.neurobiolaging.2019.02.013. Epub 2019 Feb 27.

PMID:
31128566
46.

NFL is a marker of treatment response in children with SMA treated with nusinersen.

Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, Rostasy K, Blennow K, Zetterberg H, Tulinius M.

J Neurol. 2019 Sep;266(9):2129-2136. doi: 10.1007/s00415-019-09389-8. Epub 2019 May 23.

47.

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.

Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Neri C, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2019 Jun;15(6):764-775. doi: 10.1016/j.jalz.2019.03.009. Epub 2019 May 18.

PMID:
31113759
48.

Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease.

Skillbäck T, Kornhuber J, Blennow K, Zetterberg H, Lewczuk P; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019;69(2):551-559. doi: 10.3233/JAD-190067.

PMID:
31104027
49.

Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapy-A pilot study.

Kranaster L, Blennow K, Zetterberg H, Sartorius A.

J Affect Disord. 2019 Jun 15;253:449-453. doi: 10.1016/j.jad.2019.04.080. Epub 2019 Apr 18.

PMID:
31103810
50.

CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.

Blennow K, Diaz-Lucena D, Zetterberg H, Villar-Pique A, Karch A, Vidal E, Hermann P, Schmitz M, Ferrer Abizanda I, Zerr I, Llorens F.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):846-853. doi: 10.1136/jnnp-2018-320155. Epub 2019 May 16.

PMID:
31097472

Supplemental Content

Loading ...
Support Center